serum erythrocyte sedimentation rate and C-reactive protein level (69 mm/hr ve 126 mg/L, respectively). Complete blood count and other biochemical parameters were within normal ranges. Infective and inflammatory markers were also normal (anti-DNA, ANA, C3 and C4 immunoglobulin, anti-SSA, anti-SSB, anti-SM, anti-SCL, and anti-JO). The patient was treated with topical dexamethasone 0.1 mg/5 mL ophthalmic solution hourly, cyclopentolate 1 %3 times a day, and systemic oral 1 mg/ kg/day prednisolone therapy with a plan to taper.
After one month of this combination of topical and oral steroid therapy, her best corrected visual acuity was stable and visual deterioration was resolved. Slit-lamp biomicroscopy revealed a dramatic regression in the anterior chamber reaction, with only trace anterior chamber cells/flare and few keratic precipitates ( Figure 4 ). Treatment continued with slow tapering.
Discussion
RP is a rare autoimmune disorder characterized by recurrent episodes of inflammation involving cartilaginous structures containing type 2 collagen throughout the body, resulting in tissue damage and destruction. 1 The disease causes repetitive inflammation mainly affecting the ears, nose, and tracheobronchial tract. Proteoglycan-rich structures throughout the body such as the joints, eyes, inner ear, blood vessels, heart, and kidneys may also be involved. 5 The most common early signs of RP are auricular chondritis and polyarthritis, occurring in over 80% of patients. 6 However, common symptoms are often absent in the early stages; therefore, it may mimic any other rheumatologic disease involving joint, ocular, cutaneous, or audio-vestibular dysfunction, resulting in diagnostic delays.
Ocular manifestations are found in 50-70% of patients and are of great importance since they are correlated with disease activity. 7 Although two major ocular manifestations documented in the literature include episcleritis or scleritis, uveitis has also been reported in 3-22% of cases and can compromise visual outcomes. 7 Uveitis, though uncommon, is reported to be anteriorly located and non-granulomatous. This is consistent with the present case, which presented with bilateral anterior uveitis concurrent with chondritis of one ear, the knees, and fingers. The diagnostic criteria for RP are based on characteristic clinical manifestations. Biopsy confirmation may be needed if the diagnosis is suspected. In our case, biopsy did not seem crucial, since the auricular chondritis was typical as an early manifestation of her disease. Although RP is most common in patients between the ages of 40 and 60, 1 it can also affect young adults or children, as in the present case. The prognosis of patients with RP is also variable and depends on the organ involvement and response to treatment. 8 Treatment is customized according to the severity and site of the disease. Mild forms are treated with anti-inflammatory and anti-neutrophilic agents but advanced cases, including those involving acute airway obstruction, multiple relapses, and cardiovascular disease, may require high doses of prednisone (1 mg/kg per day) or even intravenous pulse methylprednisolone. 6 In our case, topical steroids and low-dose oral prednisolone treatment was administered initially. Because response to treatment was slow and the chondritis and uveitis were controlled only to a limited degree, the oral prednisolone dose was increased gradually to the maximum level of 1 mg/kg. This effectively reduced disease activity.
To sum up, RP is an inflammatory disease of unknown etiology that affects the connective tissue. The diagnosis is difficult to confirm and it is even more challenging to predict and manage disease progression. Ocular manifestations, although not rare, should be evaluated carefully, as relatively less common presentations such as uveitis can lead to vision loss if not detected and treated.
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